With revolutionary cell-based therapies for cancer approaching reality, CAR-T developers must address a
key challenge: how to manufacture high-quality, clinical-grade CAR-T cells at scale to provide these
groundbreaking treatments to as many patients as possible.
Traditional cell processing methodologies that work on narrow streams of slowly moving suspended
cells are manual and time consuming, presenting an obstacle to the large-scale manufacture of infused
In contrast, Cesca is developing CAR-TXpress™, which is an automated solution that isolates target cells using patented
buoyancy-activated cell separation (BACS) technology. CAR-TXpress integrates multi-component
automation steps, from T-cell isolation, purification, culture expansion and washing, and single cassette-
based automated -196°C cryopreservation and retrieval, resulting in greater cell yields and higher
consistency than other cell isolation processes. The CAR-TXpress system can provide a comprehensive and
commercially viable, automated cellular manufacturing and control (CMC) solution for the development
of CAR-T and CAR-NK therapeutics. CAR-TXpress works in bulk volumes of cells, dramatically reducing
both processing time and the cost of the required capital equipment.
On July 10, 2017, Cesca Therapeutics announced that its wholly-owned subsidiary, ThermoGenesis
Corp., acquired the cell processing systems of privately-held Syngen Inc. under an asset acquisition
agreement. For more information: www.syngeninc.com.